Why Shares of Anacor Pharma Crumbled Today


Anacor Pharmaceuticals announced today that its onychomycosis drug tavaborole successfully met both its primary and secondary endpoints in its first phase 3 trial. Rather than celebrate this news, however, investors saw shares drop around 20% today. Why did this happen?Could the fall have something to do with a rival drug that Valeant Pharmaceuticals is seeking FDA approval for? In this video, health care analyst Max Macaluso breaks down this news.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Why Shares of Anacor Pharma Crumbled Today originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.